Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CA3 | P07451 | 1/20 | 1.00 |
| ▸ | MTNR1A | P48039 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.79 |
| ▸ | ACHE | P22303 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Benzyloxycoumarin SCHEMBL29365449 | 1.00 | MAOB (1.00) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL3592957 | 0.90 | MAOB (0.81) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL21647395 | 0.87 | MAOB (0.77) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL29858559 | 0.85 | MAOB (0.75) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL28440199 | 0.85 | MAOB (1.00) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL3408787 | 0.85 | MAOB (0.75) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL29724665 | 0.85 | MAOB (1.00) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL16516672 | 0.85 | MAOB (0.75) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL29941241 | 0.85 | MAOB (0.73) | MAOBNPC1CA12CA1CA4 | |
| SCHEMBL28769917 | 0.85 | MAOB (0.73) | MAOBNPC1CA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277297-A1 | Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2012-11-01 | — | — | US | claimed |
| CN-101437510-A | A pharmaceutical composition useful as acetyl cholinesterase inhibitors | COUNCIL SCIENT IND RES (IN) | 2009-05-20 | — | — | CN | claimed |
| EP-2001463-A1 | A PHARMACEUTICAL COMPOSITION USEFUL AS ACETYL CHOLINESTERASE INHIBITORS | Council of Scientific and Industrial Research (IN) | 2008-12-17 | — | — | EP | claimed |
| US-20080009544-A1 | Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-01-10 | — | — | US | claimed |
| WO-2007107846-A1 | A PHARMACEUTICAL COMPOSITION USEFUL AS ACETYL CHOLINESTERASE INHIBITORS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-27 | — | — | WO | claimed |
| US-20230080477-A1 | PROCESS OF SYNTHESIS OF NOVEL CHROMIUM (III) COMPLEXES OF SCHIFF BASE LIGANDS AND THEIR USE THERE OF AS THERAPEUTIC AGENTS | KOTHARI richa (IN) | 2023-03-16 | — | — | US | disclosed |
| US-11505523-B2 | HDAC8 inhibitors for treating cancer | CITY OF HOPE (US) | 2022-11-22 | — | — | US | disclosed |
| CN-107050019-B | Application of 7-hydroxycoumarin pyrazoline derivative in preparation of drugs for stabilizing atherosclerotic plaques | 山东大学 | 2020-04-10 | — | — | CN | disclosed |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-24 | — | — | US | disclosed |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-24 | — | — | US | disclosed |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | CITY OF HOPE (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | CITY OF HOPE (US) | 2019-06-04 | — | — | US | disclosed |
| EP-1768675-A1 | COMBINATION THERAPIES EMPLOYING NICOTINIC ACID DERIVATIVES OR FIBRIC ACID DERIVATIVES | Medicure International Inc. (CA) | 2007-04-04 | — | — | EP | disclosed |
| EP-1703911-A1 | COMBINATION THERAPIES EMPLOYING A COMPOSITION COMPRISING A HMG COA REDUCTASE INHIBITOR AND A VITAMIN B6 RELATED COMPOUND | Medicure International Inc. (CA) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006005173-A1 | COMBINATION THERAPIES EMPLOYING NICOTINIC ACID DERIVATIVES OR FIBRIC ACID DERIVATIVES | MEDICURE INTERNATIONAL INC. (CA) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005060975-A1 | COMBINATION THERAPIES EMPLOYING A COMPOSITION COMPRISING A HMG COA REDUCTASE INHIBITOR AND A VITAMIN B6 RELATED COMPOUND | MEDICURE INTERNATIONAL INC. (CA) | 2005-07-07 | — | — | WO | disclosed |
| US-6207404-B1 | SUBJECTING THE CYTOCHROME P450 ENZYME AND THE COUMARIN BASED COMPOUND TO CONDITIONS WHEREBY THE CYTOCHROME P450 ENZYME CATALYZES THE CONVERSION OF THE COUMARIN BASED COMPOUND TO A FLUORESCENT PRODUCT | GENTEST CORPORATION | 2001-03-27 | — | — | US | disclosed |
| EP-0363793-B1 | ARYL ALKOXY COUMARINS, PROCESS FOR THEIR PRODUCTION AND THERAPEUTIC AGENTS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1993-04-21 | — | — | EP | disclosed |
| US-5100914-A | Monoamine Oxidase Inhibitors, Central Nervous System Disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-03-31 | — | — | US | disclosed |
| EP-0363793-A1 | Aryl alkoxy coumarins, process for their production and therapeutic agents containing them | BASF Aktiengesellschaft (DE) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009544-A1 | Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors | ACHE, BCHE, CHRNB1 | MAOB 291/4885NPC1 671/4885CA12 815/4885 |
| US-11505523-B2 | HDAC8 inhibitors for treating cancer | HDAC8, HDAC1, HDAC7 | MAOB 4158/4885NPC1 1115/4885CA12 2529/4885 |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | HDAC8, HDAC1, HDAC7 | MAOB 4158/4885NPC1 1115/4885CA12 2529/4885 |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | MAOB 4158/4885NPC1 1115/4885CA12 2529/4885 |
| US-20120277297-A1 | Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors | ACHE, BCHE, CYP3A7 | MAOB 84/4885NPC1 1194/4885CA12 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.